GBT Announces Participation at the Stifel 2020 Virtual Healthcare Conference
Global Blood Therapeutics (GBT) will engage in a virtual fireside chat at the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 2:00 p.m. ET. The event will be accessible via live webcast on GBT’s website, with an archived replay available for a month post-event.
GBT focuses on developing treatments for sickle cell disease, having launched Oxbryta (voxelotor), the first FDA-approved treatment of its kind, and is advancing pipeline programs targeting pain crises and hemoglobin S polymerization.
- Participation in a significant healthcare conference may enhance visibility among investors.
- The company has a strong focus on addressing sickle cell disease with innovative treatments, showcasing ongoing commitment to improve patient care.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020, at 2:00 p.m. Eastern Time.
The fireside chat will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for one month following the event.
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601, the company’s next generation hemoglobin S polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next wave of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact Information:
Steven Immergut (investors and media)
650-410-3258
simmergut@gbt.com
FAQ
What is GBT's participation in the Stifel 2020 Virtual Healthcare Conference?
What time will GBT's fireside chat take place?
Where can I watch GBT's conference presentation?
What treatments is GBT developing for sickle cell disease?
